Alpha Dna Investment Management LLC Fate Therapeutics Inc Transaction History

Alpha Dna Investment Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 31, 2023	BUY	$4.76 - $6.59 $702,818 - $973,020	147,651 New	147,651 $702,000
Q4 2022 Jan 27, 2023	BUY	$9.86 - $23.83 $1.01 Million - $2.43 Million	102,094 New	102,094 $0
Q2 2021 Aug 10, 2021	SELL	$67.25 - $92.52 $4,236 - $5,828	-63 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$72.16 - $117.4 $1,154 - $1,878	16 Added 34.04%	63 $4,000
Q4 2020 Mar 24, 2021	BUY	$38.09 - $100.95 $1,790 - $4,744	47 New	47 $4,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $215M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Alpha Dna Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Dna Investment Management LLC with notifications on news.